1692105e-13d3-45ca-ab70-e6aed396c8c0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77.4182067077344
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.580
- ALLOGRAFT_REJECTION+0.470
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.330
- COMPLEMENT+0.280
- APICAL_SURFACE+0.220
- IL2_STAT5_SIGNALING+0.190
- SPERMATOGENESIS+0.190
- E2F_TARGETS+0.170
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ANGIOGENESIS-0.410
- WNT_BETA_CATENIN_SIGNALING-0.310
- TGF_BETA_SIGNALING-0.300
- MYOGENESIS-0.260
- NOTCH_SIGNALING-0.260
- UV_RESPONSE_DN-0.240
- HYPOXIA-0.210
- BILE_ACID_METABOLISM-0.190
- OXIDATIVE_PHOSPHORYLATION-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_11_0107_E3_S77 | — | D | 0.835 |
| 2 | TCGA-A8-A08I-01A-11R-A00Z-07 | — | C | 0.825 |
| 3 | 1f57edd1-3bc9-4eaf-8045-8984d5c7f148 | — | — | 0.816 |
| 4 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.815 |
| 5 | SRR33532827 | — | D | 0.811 |
| 6 | TCGA-AO-A128-01A-11R-A10J-07 | — | D | 0.811 |
| 7 | SRR8518190 | — | D | 0.808 |
| 8 | ERR2208913 | — | — | 0.807 |
| 9 | SRR8518291 | — | D | 0.798 |
| 10 | SRR8613787 | — | D | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |